Gossamer Bio, Inc.

GOSS Healthcare Biotechnology

Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024. In the quarter to June 2026, revenue fell 19.6%, EPS grew 129.4%, free cash flow grew 16.3% and total debt fell 81.7%, each against the same quarter a year earlier.

8.66 0.23 −2.59%
Market cap
$54.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
n/a
Altman Z
−12.52
Beneish M
0.74
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
178.72% 215.10% 365.33% 1,107.65%

+8 more TTM periods

ROA
(78.81%) (88.11%) (69.89%) (55.80%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
192.64% (264.94%) (163.39%) (110.02%)
Average Days of Receivables
41.82 60.81 92.07 76.59
Free Cash Flow per Share
(40.65) (58.18) (59.98) (55.66)
Free Cash Flow
(162.63) (170.26) (171.34) (158.61)
Other line items

Show all line items

Columns are period end dates